CSL Behring’s state-of-the-art plasma processing facility in Broadmeadows, Victoria, has been awarded the 2025 Facility of the Year in the Pharma 4.0 category by the International Society for Pharmaceutical Engineering (ISPE).
The award recognises the facility’s advanced use of digital technologies and automation in pharmaceutical manufacturing, the company said in a news release.
Now fully operational, the site is the largest plasma fractionation facility of its kind globally and has increased CSL Behring’s local processing capacity ninefold, now handling over 10 million litres of plasma annually.
“Projects like our Broadmeadows Plasma Fractionation Facility enable us to meet patients’ needs with greater flexibility and efficiency. This initiative not only enhances our plasma processing capabilities but also sets a new standard for future projects across our global manufacturing network,” said Laura O’Brien, head of Global Manufacturing at CSL Behring.
“Being announced the category winner for Pharma 4.0 underscores our commitment to innovation and transformation in pharmaceutical manufacturing”.
The facility features a “digital twin” – a virtual model of the plant – alongside advanced robotics and automation, boosting safety, reducing waste, and increasing operational efficiency.
Its modular design supports future upgrades and sustainability efforts, including reusable filters and energy-saving systems. A fully automated warehouse with robotic vehicles further streamlines operations.
Andrew Hodder, Manufacturing and Site Head at CSL Behring Broadmeadows, said the recognition reflects the company’s long-term investment in Australian biopharmaceutical manufacturing.
“This facility builds on our proud Australian heritage and represents a bright future for our Broadmeadows site and biopharma manufacturing in Australia,” he said.
CSL Behring said the facility will play a key role in expanding global access to plasma-based therapies for immune disorders, bleeding conditions and trauma care.
